M. Poudenx

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

Marius Ilié, Élodie Long-Mira, Coraline Bence et al. · Annals of Oncology · 2015 · 584 citations

Medicine, Oncology, Pathology +13

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011 · 575 citations

Medicine, Geriatric Medicine, Oncology +10

Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker

Véronique Hofman, Christelle Bonnetaud, Marius Ilié et al. · Clinical Cancer Research · 2010 · 315 citations · Full text

Medicine, Oncology, Pathology +17

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

M. Pérol, C. Chouaïd, David Pérol et al. · Journal of Clinical Oncology · 2012 · 233 citations

Medicine, Oncology, Pharmacology +13

Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

Jean-Louis Pujol, Jean Pierre Daurès, Aart Brutel de la Rivière et al. · JNCI Journal of the National Cancer Institute · 2001 · 173 citations

Medicine, Oncology, Pharmacology +15